Myriad Genetics Inc (MYGN)

19.23
0.07 0.39
NASDAQ : Services
Prev Close 19.15
Open 19.22
Day Low/High 19.07 / 19.49
52 Wk Low/High 28.82 / 46.24
Volume 313.30K
Avg Volume 1.71M
Exchange NASDAQ
Shares Outstanding 68.09M
Market Cap 1.31B
EPS 1.80
P/E Ratio 22.30
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABCO, AEGN, AVGO, GKOS, GPT, GTN, MYGN, SINO, THRM Downgrades: AN, CODI, PRGX, TAIT, TREC Initiations: BMCH Read on to get TheStreet Quant Ratings' detailed report:

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

Finding the stocks that have changed direction.

GeneSight® Psychotropic Test Demonstrated Substantial Cost Savings For Payers In New Study Published In Clinical Therapeutics

GeneSight® Psychotropic Test Demonstrated Substantial Cost Savings For Payers In New Study Published In Clinical Therapeutics

Economic Utility Study Showed Annual Cost Savings of $3,988 per Member

Myriad's Prolaris® Test Significantly Improves The Risk Classification For One Third Of Men Diagnosed With Localized Prostate Cancer

Myriad's Prolaris® Test Significantly Improves The Risk Classification For One Third Of Men Diagnosed With Localized Prostate Cancer

New Data from 16,000 Patient Study to Be Presented at 2017 ASCO GU

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments

Cramer points to Gilead's pipeline for its problems.

Noteworthy Friday Option Activity: MYGN, SEMG, BOBE

Noteworthy Friday Option Activity: MYGN, SEMG, BOBE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Myriad Genetics, Inc. , where a total volume of 52,093 contracts has been traded thus far today, a contract volume which is representative of approximately 5.2 million underlying shares (given that every 1 contract represents 100 underlying shares).

The EndoPredict® Test Receives Positive Coverage Decisions From Multiple Blue Cross Blue Shield Affiliate Plans

The EndoPredict® Test Receives Positive Coverage Decisions From Multiple Blue Cross Blue Shield Affiliate Plans

Coverage Decisions Expand Access to More Than 32 Million Patients

EndoPredict® Reviewed By Blue Cross Blue Shield Association's Evidence Street

EndoPredict® Reviewed By Blue Cross Blue Shield Association's Evidence Street

The Level of Evidence for EndoPredict Consistent with that of First-Generation Test

Positive Clinical Utility Results Of Crescendo's Vectra® DA Test For Rheumatoid Arthritis Published In The Journal Arthritis & Rheumatology

Positive Clinical Utility Results Of Crescendo's Vectra® DA Test For Rheumatoid Arthritis Published In The Journal Arthritis & Rheumatology

Vectra DA Test Guides Treatment for Rheumatoid Arthritis Patients that are Methotrexate-Incomplete Responders

Myriad Genetics Will Present Results From Six Breast Cancer Studies At SABCS

Myriad Genetics Will Present Results From Six Breast Cancer Studies At SABCS

New Data on EndoPredict®, myRisk™ Hereditary Cancer and myChoice® HRD

Crescendo Bioscience Announces Four Studies With Vectra® DA Will Be Presented At The American College Of Rheumatology 2016 Annual Meeting

Crescendo Bioscience Announces Four Studies With Vectra® DA Will Be Presented At The American College Of Rheumatology 2016 Annual Meeting

Studies Advance the Knowledge of Vectra DA Utility for Clinicians and Patients with RA

Myriad Will Seek Japanese Regulatory Approval For BRACAnalysis CDx®

Myriad Will Seek Japanese Regulatory Approval For BRACAnalysis CDx®

Expands Its Companion Diagnostic Collaboration with AstraZeneca

The GeneSight® Precision Medicine Test Drives Significant Medication Cost Savings In Patients With Generalized Anxiety Disorder

The GeneSight® Precision Medicine Test Drives Significant Medication Cost Savings In Patients With Generalized Anxiety Disorder

New Data Will Be Presented at the NEI Psychopharmacology Congress

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AYR, CRCM, TG Downgrades: ADPT, AMZN, ANGI, ARNC, BKD, BWXT, CAJ, CALX, CSGP, EMR, HZO, LXRX, MNK, MYGN, NTRA, PBI, TCO, TRI Initiations: PFGC Read on to get TheStreet Quant Ratings' detailed report:

The Myriad MyPath® Melanoma Test Effectively Diagnosed Patients In The Largest Outcomes-Based Study For A Melanoma Diagnostic

The Myriad MyPath® Melanoma Test Effectively Diagnosed Patients In The Largest Outcomes-Based Study For A Melanoma Diagnostic

Data Being Presented at ASDP Demonstrate a Diagnostic Accuracy of >95 Percent

Myriad Genetics Teams Up With Project BioEYES To Advance STEM Education In Utah

Myriad Genetics Teams Up With Project BioEYES To Advance STEM Education In Utah

Employees Will Facilitate Classroom Learning and Inspire Students to Pursue Careers in Science